Back to Journals » Biologics: Targets and Therapy » Volume 15

Biologic Treatments of Psoriasis: An Update for the Clinician

Authors Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J

Received 16 October 2020

Accepted for publication 31 December 2020

Published 16 February 2021 Volume 2021:15 Pages 39—51

DOI https://doi.org/10.2147/BTT.S252578

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Shein-Chung Chow


Video abstract presented by Nicholas Brownstone.

Views: 81

Nicholas D Brownstone, Julie Hong, Megan Mosca, Edward Hadeler, Wilson Liao, Tina Bhutani, John Koo

University of California, San Francisco, Department of Dermatology, Psoriasis and Skin Treatment Center, San Francisco, CA, USA

Correspondence: Nicholas D Brownstone
University of California, San Francisco, Department of Dermatology, Psoriasis and Skin Treatment Center, 515 Spruce Street, San Francisco, CA, 94118, USA
Tel +1 415-476-4019
Fax +1 415-502-4126
Email Nicholas.Brownstone@ucsf.edu

Abstract: The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced. However, the fact that there are so many available options has also caused confusion for providers. Therefore, this manuscript deliberately focuses on the most clinically useful facts (such as efficacy and safety data) about each and every FDA approved biologic agent (including pipeline agents) for psoriasis. Moreover, among the clinically relevant facts, this manuscript purposely emphasizes the unique merits and demerits of each agent to make it easier for the provider to select which one of these many options is the best for the particular patient on hand. The goal of this manuscript is to aid the busy practicing dermatologist in becoming more adept at using these agents with the ultimate aim of improving patient care.

Keywords: biologic therapy, psoriasis, IL-17, TNF-alpha, IL 12/23, psoriatic arthritis, IL-23

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]